In the field of autoimmune disease drugs, the Dabear version of Upadacitinib from Laos is gradually becoming a new hope for patients in low- and middle-income regions, leveraging its active ingredient highly consistent with the original drug and significant price advantages.
What are the purchase channels for the Dabear version of Upadacitinib from Laos?
The Dabear version of Upadacitinib from Laos is available in the specification of 15mg*30 tablets/box. For specific purchasing methods, we recommend adding our professional customer service for detailed consultation.
Usage, dosage, and adverse reactions of Upadacitinib
For patients who have obtained a prescription for Upadacitinib, correct medication administration is crucial. According to the drug label, the recommended dose of Upadacitinib is 15 mg (equivalent to one tablet) once daily orally. Patients may choose to use Upadacitinib as monotherapy or in combination with methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The specific regimen should be determined by the attending physician based on the patient's condition. It is important to note that Upadacitinib tablets should be swallowed whole, not split, crushed, or chewed, to ensure the sustained-release properties of the drug are not compromised. During the use of Upadacitinib, patients may experience some adverse reactions. Common adverse reactions include upper respiratory tract infections (such as common cold, sinusitis), nausea, cough, and fever. Although most adverse reactions are mild to moderate, vigilance is required for serious adverse reactions such as pneumonia and cellulitis. Patients should closely monitor changes in their symptoms during treatment. If signs of infection (such as persistent high fever, chills, worsening cough) or any unusual discomfort occur, they should contact their doctor immediately. The doctor will assess whether to continue the medication or adjust the treatment plan based on the patient's specific situation. Correctly recognizing and proactively reporting adverse reactions is an important part of ensuring medication safety.
Clinical progress of Upadacitinib across multiple indications
In addition to the FDA-approved indication for rheumatoid arthritis, Upadacitinib is actively expanding its therapeutic landscape worldwide. In October 2019, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, recommending approval of Upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). This means that RA patients in the European Union will soon benefit from this new drug as well. In November of the same year, AbbVie announced positive results from the Phase III SELECT-PsA2 study (NCT03104374) evaluating Upadacitinib for the treatment of psoriatic arthritis (PsA). The study assessed the efficacy and safety of Upadacitinib (15 mg and 30 mg once daily) in patients with PsA, and the results showed the study was successful, laying the foundation for the submission of the PsA indication. Also in November 2019, at the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARP) Annual Meeting held in Atlanta, USA, AbbVie presented positive data from the Phase II/III SELECT-AXIS1 trial (NCT03178487) of Upadacitinib in adult patients with active ankylosing spondylitis (AS). The results showed that compared with placebo, Upadacitinib significantly improved the signs and symptoms of active ankylosing spondylitis. These positive clinical data indicate that Upadacitinib not only performs well in the treatment of RA but also holds promise as a new oral treatment option for patients with psoriatic arthritis and ankylosing spondylitis in the future.
